MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company developing OPT101 as an innovative treatment for patients on peritoneal dialysis ...
MUTTENZ, Switzerland, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Opterion Health AG today announced that the first patient has been successfully enrolled in its Phase 1 SPARC trial. This marks the official ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results